Skip to Main Content

Amicus Therapeutics (FOLD) announced negative results Wednesday from a late-stage clinical trial of an experimental topical medicine for patients suffering from a rare, inherited skin-blistering disease.

In the phase 3 clinical trial, the Amicus drug SD-101 did no better than placebo in healing wounds in patients with epidermolysis bullosa.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!